University of Virginia School of Medicine researchers have discovered a rare and powerful type of immune cell in the meninges around the brain, suggesting the cells may play a critical but previously unappreciated role in battling Alzheimer’s disease, multiple sclerosis, meningitis and other neurological diseases, in addition to supporting our healthy mental functioning. By harnessing the cells’ power, doctors may be able to develop new treatments for neurological diseases, traumatic brain injury and spinal cord injuries – even migraines.
Further, the researchers suspect the cells may be the missing link connecting the brain and the microbiota in our guts, a relationship already shown important in the development of Parkinson’s disease.
Unexpected Presence
The cells, known as “type 2 innate lymphocytes,” previously have been found in the gut, lungs and skin – the body’s barriers to disease. Their discovery in the meninges, the membranes surrounding the brain, comes as a surprise.
They were found as UVA researcher Jonathan Kipnis explored the implications of his lab’s game-changing discovery last year that the brain and the immune system are directly connected via vessels long thought not to exist.
niversity of Virginia School of Medicine researchers have discovered a rare and powerful type of immune cell in the meninges around the brain, suggesting the cells may play a critical but previously unappreciated role in battling Alzheimer’s disease, multiple sclerosis, meningitis and other neurological diseases, in addition to supporting our healthy mental functioning. By harnessing the cells’ power, doctors may be able to develop new treatments for neurological diseases, traumatic brain injury and spinal cord injuries – even migraines.
Further, the researchers suspect the cells may be the missing link connecting the brain and the microbiota in our guts, a relationship already shown important in the development of Parkinson’s disease.
Unexpected Presence
The cells, known as “type 2 innate lymphocytes,” previously have been found in the gut, lungs and skin – the body’s barriers to disease. Their discovery in the meninges, the membranes surrounding the brain, comes as a surprise.
They were found as UVA researcher Jonathan Kipnis explored the implications of his lab’s game-changing discovery last year that the brain and the immune system are directly connected via vessels long thought not to exist.
niversity of Virginia School of Medicine researchers have discovered a rare and powerful type of immune cell in the meninges around the brain, suggesting the cells may play a critical but previously unappreciated role in battling Alzheimer’s disease, multiple sclerosis, meningitis and other neurological diseases, in addition to supporting our healthy mental functioning. By harnessing the cells’ power, doctors may be able to develop new treatments for neurological diseases, traumatic brain injury and spinal cord injuries – even migraines.
Further, the researchers suspect the cells may be the missing link connecting the brain and the microbiota in our guts, a relationship already shown important in the development of Parkinson’s disease.
Unexpected Presence
The cells, known as “type 2 innate lymphocytes,” previously have been found in the gut, lungs and skin – the body’s barriers to disease. Their discovery in the meninges, the membranes surrounding the brain, comes as a surprise.
They were found as UVA researcher Jonathan Kipnis explored the implications of his lab’s game-changing discovery last year that the brain and the immune system are directly connected via vessels long thought not to exist.
“These cells are potentially the mediator between the gut and the brain. They are the main responder to microbiota changes in the gut. They may go from the gut to the brain, or they may just produce something that will impact those cells. But you see them in the gut and now you see them also in the brain,” Kipnis said. “We know the brain responds to things happening in the gut. Is it logical that these will be the cells that connect the two? Potentially. We don’t know that, but it very well could be.”
While much more research needs to be done to understand the role of these cells in the meninges, Gadani noted that it’s almost certain that the cells are important in a variety of neurological conditions.
“It would be inconceivable they’re not playing a role in migraines and certain conditions like that,” he said. “The long-term goal of this would be developing drugs for targeting these cells. I think it could be highly efficacious in migraine, multiple sclerosis and possibly other conditions.”
Learn more: UNKNOWN SOLDIERS: UVA DISCOVERS POWERFUL DEFENDERS OF THE BRAIN
[osd_subscribe categories=’immune-therapies’ placeholder=’Email Address’ button_text=’Subscribe Now for any new posts on the topic “IMMUNE THERAPIES”‘]
Receive an email update when we add a new IMMUNE THERAPIES article.
The Latest on: Type 2 innate lymphocytes
[google_news title=”” keyword=”type 2 innate lymphocytes” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Yype 2 innate lymphocytes
- Is the FDA Pressing Pause on More Cancer Trials? It's Hard to Tellon April 24, 2024 at 6:41 am
Clinical trial holds delay therapies getting to market and may be on the rise in oncology. But there's a lot the public doesn't know about how often these holds happen and why.
- Natural Killer (NK) Cell Therapy Pipeline Research Report 2024: Comprehensive Insights About 100+ Companies and 185+ Pipeline Drugson April 19, 2024 at 4:35 am
The "Natural Killer (NK) cell therapy - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.This "Natural Killer (NK) cell therapy - Pipeline Insight, 2024," ...
- Sanofi announces new 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosison April 19, 2024 at 12:29 am
Sanofi announces new 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis: Paris Friday, April 19, 2024, 13:00 Hrs [IST] Sanofi’s ...
- Sanofi’s Frexalimab Shows Promise in Phase 2 for Treating Multiple Sclerosison April 17, 2024 at 7:24 am
Sanofi's experimental CD40L antibody, frexalimab, demonstrates encouraging results in a 48-week phase 2 study for relapsing multiple sclerosis (M ...
- Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosison April 16, 2024 at 10:35 pm
New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosisData support frexalimab as a potential ...
- Sanofi - Aventis Groupe: Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosison April 16, 2024 at 10:25 pm
New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis Data support frexalimab as a potential first-in-class, high-efficacy, non-lymphocyte depleting ...
- Oncolytics Biotech® Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDAon April 11, 2024 at 4:00 am
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapeutics for oncology, is pleased to announce the submission of a Type C meeting request ...
- Soligenix Announces Agreement on the Design of a Second Confirmatory Placebo-Controlled Trial for HyBryte™ With the European Medicines Agencyon April 3, 2024 at 12:30 am
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet ...
via Bing News